Abstract
Adherence to oral HIV pre-exposure prophylaxis (PrEP) is crucial for its effectiveness, however, studies have shown that PrEP use wanes within the first six months. We sought to understand reasons for discontinuation among individuals previously accessing PrEP from HIV clinics. Between November 2020 - January 2023, we conducted a mixed methods sub-study within a programmatic study to improve the efficiency of PrEP delivery in four public HIV clinics in Kenya (ClinicalTrials.gov number NCT04424524). We used random simple stratification to select individuals who had discontinued PrEP and completed surveys; we purposively sampled a subset of participants for in-depth interviews. Quantitative data were analyzed descriptively; qualitative data were analyzed thematically guided by the socio-ecological model. Overall, 300 participants completed surveys; median age was 35 years (interquartile range 28-43), 61% were female and 57% were married/cohabiting. Majority (76%) discontinued PrEP because of low perceived risk of HIV acquisition. Nearly half (43.7%) reported not being at risk, 23% had separated from their partners or had partners who were virally suppressed (6%), 3.3% were discontinued by healthcare providers. Other reasons for discontinuation were PrEP use concerns (15.6%) including concerns about side effects (8.7%) and daily pill burden (6%). Accessibility challenges (4%), and opportunity costs such as fear of missing/losing work (1%) were reported less frequently. Similarly in qualitative interviews, participants (n=30) reported PrEP discontinuation was mainly driven by perceived low HIV risk due to changes in relationship dynamics (separation/partner relocation), partner achieving viral suppression for those in serodifferent partnerships and reduced sexual activity (individual and interpersonal factors). Other themes included perceived HIV/PrEP stigma (community factors), frequency of clinic visits and long wait times (structural/institutional factors). PrEP discontinuation was mainly associated with perceived low HIV risk in this study population. Prevention-effective adherence counselling is essential in supporting individuals to correctly assess HIV risk to inform appropriate discontinuation.